Coronavirus: Japan approves Gilead's remdesivir for COVID-19 treatment

Coronavirus: Japan approves Gilead's remdesivir for COVID-19 treatment

Coronavirus: Japan approves Gilead's remdesivir for COVID-19 treatment

"This is an emergency use drug, so the federal government will certainly want to make this drug available to everyone who needs it", Steven Roth, a partner and intellectual property attorney with Lucas & Mercanti, LLP in NY, said.

Japan plans to authorize Thursday the antiviral drug remdesivir to treat coronavirus patients, the government said, with an eye to approving another medication Avigan this month.

As for remdesivir, Gilead will have to transfer the technology to make the active pharmaceutical ingredients (APIs) in India, post which the formulation, which is an injectable, can be made.

This would make Japan the second country to approve the drug after U.S. regulators authorized it on Friday for emergency use against severe cases of COVID-19.

Meanwhile, a Brotish wire service reported that Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus.

The speedy process shows how desperate the Japanese government is about finding any drug that can work against the novel coronavirus in the ongoing pandemic.

However, it is worth noting that Gilead Sciences, the company that has developed Remdesivir, holds a patent that allows the drug to be manufactured only for research, not commercialization.

Magnús Gottfreðsson, infectious disease specialist at Landspítali National University Hospital, states that the drug will be used to treat COVID-19 patients in Iceland who are seriously ill. But doctors across the country, particularly in COVID-19 hotspots like NY and Boston, became concerned after being denied their request to obtain the new therapy, IDSA president Dr. Thomas File told Reuters on Thursday.

However, a study by a Chinese group found no statistically significant difference in both the fatality rate and the pace of recovery.

Multiple trials of remdesivir are nonetheless beneath manner. "Japan should have only approved the drug after conducting its own clinical tests to confirm its effectiveness and safety".

"With reported COVID-19 infections not declining as perceptibly as most models had originally predicted... we now believe in our base case GILD would only be able to supply the medicine to ~1/3 of USA pts who could benefit from it throughout the summer" he continued.

Related news



[an error occurred while processing the directive]